Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on ...

If you're interested in broad exposure to the Large Cap Blend segment of the US equity market, look no further than the Vanguard Mega Cap ETF (MGC), a passively managed exchange traded fund launched ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.

Cathie Wood, founder and CEO of ARK Invest, has cemented her reputation as a visionary investor with a knack for identifying ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

The largest transaction of the day was ARK’s acquisition of 102,806 shares of CRISPR Therapeutics AG (NASDAQ: CRSP ), valued at approximately $5.26 million. This purchase through the ARKK ETF reflects ...

Regenerative medicine is gaining serious momentum in 2025 as scientific advances, regulatory progress, and payer acceptance converge to push the sect ...

A smart beta exchange traded fund, the First Trust NASDAQ-100 Equal Weighted ETF (QQEW) debuted on 04/19/2006, and offers ...